Skip to main content

Search Results

Displaying: 1 - 10 of 110 Results

Continuous Evolution (PACE) of Botulinum Neurotoxins with Reprogrammed Substrate Specificity for Intracellular Protease Therapy

Biomacromolecule-based therapies are of keen interest to the pharmaceutical industry because macromolecules engage in highly specific interactions in biological systems compared to traditional small molecules. Despite their success, macromolecular…

Investigators

  • David Liu

Reproducible Individual Brain Organoids

The human brain is a highly complex organ comprised of a variety of cell types and that are largely generated during embryonic development. While this process is invariable in vivo, it is unclear if this can be recapitulated outside of the embryo.…

Investigators

  • Paola Arlotta

Cyborg organoids with fully integrated nanoelectronics

Researchers from the Liu lab at Harvard have grown organoids with fully integrated sensors that grow with the developing cells, giving them the unique ability to study the early stages of organ development. Organoids are 3D clusters of cells that…

Investigators

  • Jia Liu
  • Kewang Nan
  • Qiang Li

Faster testing for illicit drugs

Researchers in the Whitesides lab have developed a portable and easy to use Magneto-Archimedes Levitation (MagLev) device for identifying the composition of illicit drug mixtures. A diamagnetic sample (in this case, an unknown drug mixture) is…

Investigators

  • George Whitesides
  • Christoffer Abrahamsson
  • Amit Nagarkar
  • Michael Fink
  • Daniel Preston
  • Markus Nemitz
  • Shencheng Ge
  • Joseph Bozenko

Isolating live cells after high-throughput, long-term, time-lapse microscopy

Researchers led by Johan Paulsson have engineered a high-throughput microfluidic device for multigenerational culturing, imaging, and tracking of single-cell lineages. The platform is highly customizable and is compatible with many cell types,…

Investigators

  • Johan Paulsson

Machine learning to accelerate diagnostics and therapeutics for COVID-19

The COVID-19 pandemic demands a rapid response of science, diagnostics, and therapeutics. Debora Marks’ lab at Harvard Medical School aims to accelerate those efforts using predictive models of the SARS-CoV2-19 sequences and 3D structures. The lab’s…

Investigators

  • Debora Marks

Exo-site Enzyme Inhibitor Discovery Platform for Oncology Therapeutics

A startup emerging from David Liu's lab intends to commercialize a small-molecule enzyme inhibitor discovery platform to generate more potent drugs with higher specificity. (Image credit: Rose Lincoln/Harvard Staff Photographer.)Off-target drug…

Investigators

  • David Liu

Evolution of Sequence-Defined Highly Functionalized Nucleic Acid Polymers

DESCRIPTION Template-directed synthesis of modified DNA sequences can provide a rich source of material for generating new therapies featuring modified nucleic acid polymers. The Liu lab has previously developed pioneering methods to generate…

Investigators

  • David Liu

Novel platform for rapid, immunization-free nanobody discovery

This is a novel platform technology that can be used to expedite the development of nanobodies for therapeutic and diagnostic applications by avoiding the need for animal immunization.Nanobodies are single-domain antibodies derived from camelids…

Investigators

  • Andrew Kruse

SIM-PAL: proteome wide identification of small molecule binding sites

Precise target identification for small molecules is an important and essential step in drug development. Despite its importance, there are very few unbiased, proteome-wide approaches aimed at identifying binding partners for small molecules. In…

Investigators

  • Christina Woo

Page 1 of 11